Gold nanoparticles: The importance of physiological principles to devise strategies for targeted drug delivery

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 8, Issue 6, 2012, Pages 804-814

  Papasani, Madhusudhan R ^a   Wang, Guankui ^a   Hill, Rodney A ^a  

^a UNIVERSITY OF IDAHO   (United States)

Author keywords

Drug delivery; Gold nanoparticles; In vitro; In vivo; Nanotechnology; Toxicity

Indexed keywords

ANIMAL MODEL; BIOLOGICAL MOLECULE; CLINICAL TRANSLATION; EXPERIMENTAL STRATEGY; FUNCTIONALIZATIONS; GOLD NANOPARTICLE; GOLD NANOPARTICLES; IN-VITRO; IN-VIVO; LOW TOXICITY; MECHANISTIC STUDIES; MULTI-DISCIPLINARY APPROACH; PHYSIOLOGICAL PRINCIPLES; RESEARCH OPPORTUNITIES; RESEARCH PROGRESS; SURFACE CHARACTERISTICS; TARGETED DELIVERY; TARGETED DRUG DELIVERY;

GOLD ALLOYS; METAL NANOPARTICLES; NANOTECHNOLOGY; TOXICITY;

DRUG DELIVERY;

GOLD NANOPARTICLE;

BIOCOMPATIBILITY; BLOOD VESSEL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG TARGETING; EXTRACELLULAR SPACE; GENETIC TRANSFECTION; IN VITRO STUDY; IN VIVO STUDY; NANOTECHNOLOGY; NONHUMAN; PHYSICAL DISEASE BY BODY FUNCTION; PHYSIOLOGICAL PROCESS; RETICULOENDOTHELIAL SYSTEM; REVIEW; SURFACE PROPERTY;

DRUG DESIGN; GOLD; MOLECULAR TARGETED THERAPY; NANOCAPSULES; NANOTECHNOLOGY;

ANIMALIA;

EID: 84864109896     PISSN: 15499634     EISSN: 15499642     Source Type: Journal    
DOI: 10.1016/j.nano.2012.01.008     Document Type: Review

References (56)

1. Owens D.E., Peppas N.A. Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int J Pharm 2006, 307:93-102.
2. Daniel M.C., Astruc D. Gold nanoparticles: assembly, supramolecular chemistry, quantum-size-related properties, and applications toward biology, catalysis, and nanotechnology. Chem Rev 2004, 104:293-346.
3. Rosi N.L., Giljohann D.A., Thaxton C.S., Lytton-Jean A.K., Han M.S., Mirkin C.A. Oligonucleotide-modified gold nanoparticles for intracellular gene regulation. Science 2006, 312:1027-1030.
4. Giljohann D.A., Seferos D.S., Prigodich A.E., Patel P.C., Mirkin C.A. Gene regulation with polyvalent siRNA-nanoparticle conjugates. J Am Chem Soc 2009, 131:2072-2073.
5. Patel P.C., Giljohann D.A., Seferos D.S., Mirkin C.A. Peptide antisense nanoparticles. Proc Natl Acad Sci U S A 2008, 105:17222-17226.
6. Elbakry A., Zaky A., Liebl R., Rachel R., Goepferich A., Breunig M. Layer-by-layer assembled gold nanoparticles for siRNA delivery. Nano Lett 2009, 9:2059-2064.
7. Nativo P., Prior I.A., Brust M. Uptake and intracellular fate of surface-modified gold nanoparticles. ACS Nano 2008, 2:1639-1644.
8. Choi D., McIlroy D., Nagler J., Aston E., Hrdlicka P., Gustin K., et al. One-dimensional silica structures and their applications to the biological sciences. (Chapter 3). Nanostructured oxides for life sciences 2009, Vol 2:83-108. Wiley-VCH, Hoboken, NJ. S.S.R. Kumar (Ed.).
9. Lacerda S.H., Park J.J., Meuse C., Pristinski D., Becker M.L., Karim A., et al. Interaction of gold nanoparticles with common human blood proteins. ACS Nano 2010, 4:365-379.
10. Ghitescu L., Fixman A., Simionescu M., Simionescu N. Specific binding sites for albumin restricted to plasmalemmal vesicles of continuous capillary endothelium: receptor-mediated transcytosis. J Cell Biol 1986, 102:1304-1311.
11. Wang G., Papasani M.R., Cheguru P., Hrdlicka P.J., Hill R.A. Gold-peptide nanoconjugate cellular uptake is modulated by serum proteins. Nanomedicine 2011, [published on e-pub ahead of print].
12. Gao D., Tian Y., Bi S., Chen Y., Yu A., Zhang H. Studies on the interaction of colloidal gold and serum albumins by spectral methods. Spectrochim Acta A Mol Biomol Spectrosc 2005, 62:1203-1208.
13. Brewer S.H., Glomm W.R., Johnson M.C., Knag M.K., Franzen S. Probing BSA binding to citrate-coated gold nanoparticles and surfaces. Langmuir 2005, 21:9303-9307.
14. Joshi P., Chakraborty S., Dey S., Shanker V., Ansari Z.A., Singh S.P., et al. Binding of chloroquine-conjugated gold nanoparticles with bovine serum albumin. J Colloid Interface Sci 2011, 355:402-409.
15. Chithrani B.D., Ghazani A.A., Chan W.C. Determining the size and shape dependence of gold nanoparticle uptake into mammalian cells. Nano Lett 2006, 6:662-668.
16. Chithrani B.D., Chan W.C. Elucidating the mechanism of cellular uptake and removal of protein-coated gold nanoparticles of different sizes and shapes. Nano Lett 2007, 7:1542-1550.
17. Patel P.C., Giljohann D.A., Daniel W.L., Zheng D., Prigodich A.E., Mirkin C.A. Scavenger receptors mediate cellular uptake of polyvalent oligonucleotide-functionalized gold nanoparticles. Bioconjug Chem 2010, 21:2250-2256.
18. Mailander V., Landfester K. Interaction of nanoparticles with cells. Biomacromolecules 2009, 10:2379-2400.
19. Choi H.S., Liu W., Misra P., Tanaka E., Zimmer J.P., Itty Ipe B., et al. Renal clearance of quantum dots. Nat Biotechnol 2007, 25:1165-1170.
20. Deb S., Patra H.K., Lahiri P., Dasgupta A.K., Chakrabarti K., Chaudhuri U. Multistability in platelets and their response to gold nanoparticles. Nanomedicine 2011, 7:376-384.
21. Arvizo R.R., Rana S., Miranda O.R., Bhattacharya R., Rotello V.M., Mukherjee P. Mechanism of anti-angiogenic property of gold nanoparticles: role of nanoparticle size and surface charge. Nanomedicine 2011, 7:580-587.
22. Etame A.B., Smith C.A., Chan W.C., Rutka J.T. Design and potential application of PEGylated gold nanoparticles with size-dependent permeation through brain microvasculature. Nanomedicine 2011, 7:992-1000.
23. Lin I.C., Liang M., Liu T.Y., Monteiro M.J., Toth I. Cellular transport pathways of polymer coated gold nanoparticles. Nanomedicine 2012, 8:8-11.
24. Qian X., Peng X.H., Ansari D.O., Yin-Goen Q., Chen G.Z., Shin D.M., et al. In vivo tumor targeting and spectroscopic detection with surface-enhanced Raman nanoparticle tags. Nat Biotechnol. 2008, 26:83-90.
25. Chanda N., Kan P., Watkinson L.D., Shukla R., Zambre A., Carmack T.L., et al. Radioactive gold nanoparticles in cancer therapy: therapeutic efficacy studies of GA-198Au NP nanoconstruct in prostate tumor-bearing mice. Nanomedicine 2010, 6:201-209.
26. Lee S., Cha E.J., Park K., Lee S.Y., Hong J.K., Sun I.C., et al. A near-infrared-fluorescence-quenched gold-nanoparticle imaging probe for in vivo drug screening and protease activity determination. Angew Chem Int Ed Engl 2008, 47:2804-2807.
27. Cheng Y., CS A., Meyers J.D., Panagopoulos I., Fei B., Burda C. Highly efficient drug delivery with gold nanoparticle vectors for in vivo photodynamic therapy of cancer. J Am Chem Soc 2008, 130:10643-10647.
28. Menk R.H., Schultke E., Hall C., Arfelli F., Astolfo A., Rigon L., et al. Gold nanoparticle labeling of cells is a sensitive method to investigate cell distribution and migration in animal models of human disease. Nanomedicine 2011, 7:647-654.
29. Sarin H. Physiologic upper limits of pore size of different blood capillary types and another perspective on the dual pore theory of microvascular permeability. J Angiogenes Res 2010, 2:14.
30. Cleaver O., Melton D.A. Endothelial signaling during development. Nat Med 2003, 9:661-668.
31. Renkin E.M. Cellular and intercellular transport pathways in exchange vessels. Am Rev Respir Dis 1992, 146:S28-S31.
32. Marieb E.N. Human anatomy and physiology 2003, Pearson Benjamine Cummings, San Francisco. 6th ed.
33. Pries A.R., Secomb T.W., Gaehtgens P. The endothelial surface layer. Pflugers Arch 2000, 440:653-666.
34. Zhao Y.Y., Liu Y., Stan R.V., Fan L., Gu Y., Dalton N., et al. Defects in caveolin-1 cause dilated cardiomyopathy and pulmonary hypertension in knockout mice. Proc Natl Acad Sci U S A 2002, 99:11375-11380.
35. Hnasko R., Lisanti M.P. The biology of caveolae: lessons from caveolin knockout mice and implications for human disease. Mol Interv 2003, 3:445-464.
36. Simionescu M., Popov D., Sima A. Endothelial transcytosis in health and disease. Cell Tissue Res 2009, 335:27-40.
37. Bobrov V.I., Nazarova O.I., Beletskaia G.T., Agapitova I.V., Iakovlev V.P. [Interactions of sulfanilamides, penicillins and acetylsalicylic acid in serum protein binding]. Antibiot Khimioter 1988, 33:355-359.
38. Karsovskii V.I., Nagovitsyn I.A., Chudinova G.K., Savranski V.V., Karavanskii V.A. Intercation of gold nanoparticles with bovine serum albumin. Bull Lebedev Phys Inst 2007, 34:321-324.
39. Vasile E., Simionescu M., Simionescu N. Visualization of the binding, endocytosis, and transcytosis of low-density lipoprotein in the arterial endothelium in situ. J Cell Biol 1983, 96:1677-1689.
40. Soda R., Tavassoli M. Transendothelial transport (transcytosis) of iron-transferrin complex in the bone marrow. J Ultrastruct Res 1984, 88:18-29.
41. King G.L., Johnson S.M. Receptor-mediated transport of insulin across endothelial cells. Science 1985, 227:1583-1586.
42. Maeda H., Wu J., Sawa T., Matsumura Y., Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release 2000, 65:271-284.
43. Massich M.D., Giljohann D.A., Seferos D.S., Ludlow L.E., Horvath C.M., Mirkin C.A. Regulating immune response using polyvalent nucleic acid-gold nanoparticle conjugates. Mol Pharm 2009, 6:1934-1940.
44. Soutschek J., Akinc A., Bramlage B., Charisse K., Constien R., Donoghue M., et al. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 2004, 432:173-178.
45. Garnett M.C., Kallinteri P. Nanomedicines and nanotoxicology: some physiological principles. Occup Med (Lond) 2006, 56:307-311.
46. Lasagna-Reeves C., Gonzalez-Romero D., Barria M.A., Olmedo I., Clos A., Sadagopa Ramanujam V.M., et al. Bioaccumulation and toxicity of gold nanoparticles after repeated administration in mice. Biochem Biophys Res Commun 2010, 393:649-655.
47. Leuschner C., Kumar C. Nanoparticles for cancer drug delivery. Nanofabrication towards biomedical applications 2005, 289-326. Wiley-VCH, Hoboken, NJ. C. Kumar, J. Hormes, C. Leyschner (Eds.).
48. Romero E.L., Morilla M.J. Drug delivery systems against leishmaniasis? Still an open question. Expert Opin Drug Deliv 2008, 5:805-823.
49. Terentyuk G.S., Maslyakova G.N., Suleymanova L.V., Khlebtsov B.N., Kogan B.Y., Akchurin G.G., et al. Circulation and distribution of gold nanoparticles and induced alterations of tissue morphology at intravenous particle delivery. J Biophotonics 2009, 2:292-302.
50. Semmler-Behnke M., Kreyling W.G., Lipka J., Fertsch S., Wenk A., Takenaka S., et al. Biodistribution of 1.4- and 18-nm gold particles in rats. Small 2008, 4:2108-2111.
51. De Jong W.H., Hagens W.I., Krystek P., Burger M.C., Sips A.J., Geertsma R.E. Particle size-dependent organ distribution of gold nanoparticles after intravenous administration. Biomaterials 2008, 29:1912-1919.
52. Su C.H., Sheu H.S., Lin C.Y., Huang C.C., Lo Y.W., Pu Y.C., et al. Nanoshell magnetic resonance imaging contrast agents. J Am Chem Soc 2007, 129:2139-2146.
53. Chen Z., Meng H., Xing G., Chen C., Zhao Y., Jia G., et al. Acute toxicological effects of copper nanoparticles in vivo. Toxicol Lett 2006, 163:109-120.
54. Sharma A., Tandon A., Tovey J.C., Gupta R., Robertson J.D., Fortune J.A., et al. Polyethylenimine-conjugated gold nanoparticles: gene transfer potential and low toxicity in the cornea. Nanomedicine 2011, 7:505-513.
55. Choi H.S., Liu W., Liu F., Nasr K., Misra P., Bawendi M.G., et al. Design considerations for tumour-targeted nanoparticles. Nat Nanotechnol 2010, 5:42-47.
56. Burns A.A., Vider J., Ow H., Herz E., Penate-Medina O., Baumgart M., et al. Fluorescent silica nanoparticles with efficient urinary excretion for nanomedicine. Nano Lett 2009, 9:442-448.